179 related articles for article (PubMed ID: 23857432)
1. Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.
Benabbou N; Mirshahi P; Cadillon M; Soria J; Therwath A; Mirshahi M
Int J Oncol; 2013 Sep; 43(3):685-94. PubMed ID: 23857432
[TBL] [Abstract][Full Text] [Related]
2. A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line.
Benabbou N; Mirshahi P; Bordu C; Faussat AM; Tang R; Therwath A; Soria J; Marie JP; Mirshahi M
Int J Oncol; 2014 Oct; 45(4):1372-80. PubMed ID: 25095896
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
4. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Eckstein N; Servan K; Hildebrandt B; Pölitz A; von Jonquières G; Wolf-Kümmeth S; Napierski I; Hamacher A; Kassack MU; Budczies J; Beier M; Dietel M; Royer-Pokora B; Denkert C; Royer HD
Cancer Res; 2009 Apr; 69(7):2996-3003. PubMed ID: 19318572
[TBL] [Abstract][Full Text] [Related]
6. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
7. IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance.
Weiwei Z; Ya X; Wenwen W; Jia J; Jing B; Ruitao Z; Chunfang W; Ruixia G
Hum Cell; 2021 Jul; 34(4):1197-1214. PubMed ID: 33905103
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells.
An Y; Cai Y; Guan Y; Cai L; Yang Y; Feng X; Zheng J
Cancer Biother Radiopharm; 2010 Oct; 25(5):545-52. PubMed ID: 20950153
[TBL] [Abstract][Full Text] [Related]
9. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Dong L; Du M; Lv Q
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
[TBL] [Abstract][Full Text] [Related]
10. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.
Vishwamitra D; Shi P; Wilson D; Manshouri R; Vega F; Schlette EJ; Amin HM
Haematologica; 2011 Jun; 96(6):871-80. PubMed ID: 21330319
[TBL] [Abstract][Full Text] [Related]
11. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
12. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
Park GB; Kim D
Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051
[TBL] [Abstract][Full Text] [Related]
14. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway.
Chen M; Zeng J; Chen S; Li J; Wu H; Dong X; Lei Y; Zhi X; Yao L
Aging (Albany NY); 2020 Jun; 12(11):10896-10911. PubMed ID: 32516133
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of STAT3 activation by insulin-like growth factor I receptor.
Zong CS; Chan J; Levy DE; Horvath C; Sadowski HB; Wang LH
J Biol Chem; 2000 May; 275(20):15099-105. PubMed ID: 10747872
[TBL] [Abstract][Full Text] [Related]
16. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
[TBL] [Abstract][Full Text] [Related]
17. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
Chua PJ; Lim JP; Guo TT; Khanna P; Hu Q; Bay BH; Baeg GH
Int J Oncol; 2018 Dec; 53(6):2579-2589. PubMed ID: 30221675
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
[TBL] [Abstract][Full Text] [Related]
19. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract][Full Text] [Related]
20. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
